TALS

Talaris Therapeutics, Inc. [TALS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TALS Stock Summary

In the News

03:40 28 Mar 2024 TALS

3 Hot Penny Stocks to Watch Before Next Week

Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing' or fluctuations in stock prices over a short period.

12:48 28 Mar 2024 TALS

Talaris (TALS) Down on Patient Death From Renal Transplant Study

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

08:24 28 Mar 2024 TALS

Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial

Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease.

07:00 28 Mar 2024 TALS

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.

07:00 28 Mar 2024 TALS

Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.

07:00 28 Mar 2024 TALS

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:

07:59 28 Mar 2024 TALS

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at a discount to cash.

07:00 28 Mar 2024 TALS

Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.

07:00 28 Mar 2024 TALS

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.

04:01 28 Mar 2024 TALS

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.

TALS Financial details

Company Rating
Sell
Market Cap
116.44M
Income
-57.66M
Revenue
0
Book val./share
33.44
Cash/share
34.42
Dividend
1.51
Dividend %
55.58%
Employees
84
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-1.67
Forward P/E
-
PEG
0.99
P/S
-
P/B
0.77
P/C
0.08
P/FCF
-1.94
Quick Ratio
15.02
Current Ratio
15.41
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-13.74
EPS next Y
-
EPS next Q
-
EPS this Y
0.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-53.01%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
51.78%
Inst Trans
0.83%
ROA
-43%
ROE
-40%
ROC
-0.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
42.81M
Shs Float
4.21M
-
-
-
-
Target Price
-
52W Range
0.89-3.29
52W High
-
52W Low
-
RSI
48
Rel Volume
2.12
Avg Volume
142.92K
Volume
303.48K
Perf Week
0.74%
Perf Month
-
Perf Quarter
-
Perf Half Y
-4.23%
-
-
-
-
Beta
2.1789
-
-
Volatility
0.1%, 0.1%
Prev Close
0%
Price
2.72
Change
-2.16%

TALS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-28.09-34-16.53-16.66
Operating cash flow per share
-27.67-28.74-13.73-14.75
Free cash flow per share
-28.55-30.66-14.57-15.49
Cash per share
61.06223.6183.7643.95
Book value per share
-26.79221.483.3643.65
Tangible book value per share
-26.79221.483.3643.65
Share holders equity per share
-26.79221.483.3643.65
Interest debt per share
00-0.111.33
Market cap
10.37M10.86M44.53M4.21M
Enterprise value
-28.61M-6.73M25.92M-6.58M
P/E ratio
-0.58-0.48-0.92-0.06
Price to sales ratio
0000
POCF ratio
-0.59-0.57-1.11-0.07
PFCF ratio
-0.57-0.53-1.05-0.07
P/B Ratio
-0.610.070.180.02
PTB ratio
-0.610.070.180.02
EV to sales
0000
Enterprise value over EBITDA
1.590.3-0.550.09
EV to operating cash flow
1.620.35-0.650.11
EV to free cash flow
1.570.33-0.610.1
Earnings yield
-1.73-2.09-1.08-16.34
Free cash flow yield
-1.76-1.89-0.95-15.19
Debt to equity
0000.02
Debt to assets
0000.01
Net debt to EBITDA
2.170.790.40.15
Current ratio
17.8144.2930.8616.19
Interest coverage
00145.73-29.61
Income quality
0.970.850.840.82
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0.030.070.060.05
Capex to revenue
0000
Capex to depreciation
-1.48-2.88-3.91-1.41
Stock based compensation to revenue
0000
Graham number
130.13411.55176.11127.92
ROIC
1.06-0.15-0.2-0.38
Return on tangible assets
-0.43-0.15-0.19-0.35
Graham Net
-31.44217.580.8140.64
Working capital
38.5M147.35M238.53M174.15M
Tangible asset value
-17.1M148.01M242.81M180.06M
Net current asset value
-18.25M145.98M237.9M171.95M
Invested capital
0000.02
Average receivables
0187K187K0
Average payables
0717K1.66M3.22M
Average inventory
0406.5K406.5K0
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
1.05-0.15-0.2-0.38
Capex per share
-0.88-1.92-0.84-0.74

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-4.4-3.61-5-3.49-1.64
Operating cash flow per share
-3.25-3.34-4.04-3.48-1.64
Free cash flow per share
-3.33-3.4-4.12-3.53-1.64
Cash per share
46.8643.6339.6736.134.42
Book value per share
47.143.3438.6935.233.44
Tangible book value per share
47.143.3438.6935.233.44
Share holders equity per share
47.143.3438.6935.233.44
Interest debt per share
0.951.12-0.070.660.6
Market cap
10.88M4.24M7.86M12.82M12M
Enterprise value
-4.48M-6.55M-15.09M-4.5M-54.44M
P/E ratio
-0.15-0.07-0.09-0.22-0.43
Price to sales ratio
00000
POCF ratio
-0.81-0.31-0.46-0.87-1.71
PFCF ratio
-0.79-0.3-0.46-0.86-1.71
P/B Ratio
0.060.020.050.090.08
PTB ratio
0.060.020.050.090.08
EV to sales
00000
Enterprise value over EBITDA
0.230.341.041.36.1
EV to operating cash flow
0.330.470.890.317.76
EV to free cash flow
0.330.460.880.37.76
Earnings yield
-1.67-3.54-2.66-1.15-0.58
Free cash flow yield
-1.27-3.34-2.19-1.16-0.58
Debt to equity
0.020.020.010.010
Debt to assets
0.020.010.010.010
Net debt to EBITDA
0.80.561.5957.44
Current ratio
21.6116.1916.5915.4118.64
Interest coverage
-24.41-11.1915.23-9.35-4.66
Income quality
0.710.750.7511
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.030.020.020.020
Capex to revenue
00000
Capex to depreciation
-0.6-0.49-0.5-0.850
Stock based compensation to revenue
00000
Graham number
68.2759.3166.0152.6135.15
ROIC
-0.09-0.09-0.14-0.14-0.06
Return on tangible assets
-0.09-0.08-0.12-0.09-0.05
Graham Net
44.0340.3537.0733.5732.5
Working capital
188.96M174.15M158.68M146.07M142.94M
Tangible asset value
194.87M180.06M161.73M148.43M142.87M
Net current asset value
186.45M171.95M157.98M145.52M142.86M
Invested capital
0.020.020.010.010
Average receivables
00000
Average payables
2.1M3.01M3.64M3.16M1.54M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.08-0.13-0.1-0.05
Capex per share
-0.08-0.06-0.08-0.050

TALS Frequently Asked Questions

What is Talaris Therapeutics, Inc. stock symbol ?

Talaris Therapeutics, Inc. is a US stock , located in Louisville of Ky and trading under the symbol TALS

What is Talaris Therapeutics, Inc. stock quote today ?

Talaris Therapeutics, Inc. stock price is $2.72 today.

Is Talaris Therapeutics, Inc. stock public?

Yes, Talaris Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap